146 related articles for article (PubMed ID: 22201263)
1. Evaluating the epidemiology and morbidity burden associated with human papillomavirus in Israel: accounting for CIN1 and genital warts in addition to CIN2/3 and cervical cancer.
Shavit O; Raz R; Stein M; Chodick G; Schejter E; Ben-David Y; Cohen R; Arbel D; Shalev V
Appl Health Econ Health Policy; 2012 Mar; 10(2):87-97. PubMed ID: 22201263
[TBL] [Abstract][Full Text] [Related]
2. Health and economic burden of HPV-related diseases in Singapore.
Low JJ; Ko Y; Ilancheran A; Zhang XH; Singhal PK; Tay SK
Asian Pac J Cancer Prev; 2012; 13(1):305-8. PubMed ID: 22502690
[TBL] [Abstract][Full Text] [Related]
3. Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
Vaccine; 2013 Aug; 31(37):3899-905. PubMed ID: 23820080
[TBL] [Abstract][Full Text] [Related]
4. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.
Dasbach EJ; Insinga RP; Elbasha EH
BJOG; 2008 Jul; 115(8):947-56. PubMed ID: 18503574
[TBL] [Abstract][Full Text] [Related]
5. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
Drolet M; Bénard É; Pérez N; Brisson M;
Lancet; 2019 Aug; 394(10197):497-509. PubMed ID: 31255301
[TBL] [Abstract][Full Text] [Related]
6. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium.
Annemans L; Rémy V; Lamure E; Spaepen E; Lamotte M; Muchada JP; Largeron N
J Med Econ; 2008; 11(1):135-50. PubMed ID: 19450115
[TBL] [Abstract][Full Text] [Related]
7. Burden of human papillomavirus infection and related diseases in Israel.
Shavit O; Roura E; Barchana M; Diaz M; Bornstein J
Vaccine; 2013 Nov; 31 Suppl 8():I32-41. PubMed ID: 24229717
[TBL] [Abstract][Full Text] [Related]
8. Burden of HPV related anogenital diseases in young women in Germany - an analysis of German statutory health insurance claims data from 2012 to 2017.
Reuschenbach M; Mihm S; Wölle R; Schneider KM; Jacob C; Braun S; Greiner W; Hampl M
BMC Infect Dis; 2020 Apr; 20(1):297. PubMed ID: 32321435
[TBL] [Abstract][Full Text] [Related]
9. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
Van de Velde N; Boily MC; Drolet M; Franco EL; Mayrand MH; Kliewer EV; Coutlée F; Laprise JF; Malagón T; Brisson M
J Natl Cancer Inst; 2012 Nov; 104(22):1712-23. PubMed ID: 23104323
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of genital HPV infection among long-term monogamous partners of women with cervical dysplasia or genital warts-Another reason for HPV vaccination of boys.
Rob F; Tachezy R; Pichlík T; Rob L; Kružicová Z; Hamšíková E; Šmahelová J; Hercogová J
Dermatol Ther; 2017 Jan; 30(1):. PubMed ID: 27723194
[TBL] [Abstract][Full Text] [Related]
11. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
Dasbach EJ; Nagy L; Brandtmüller A; Elbasha EH
J Med Econ; 2010 Mar; 13(1):110-8. PubMed ID: 20085477
[TBL] [Abstract][Full Text] [Related]
12. Impact of HPV vaccination: health gains in the Italian female population.
Marcellusi A
Popul Health Metr; 2017 Sep; 15(1):36. PubMed ID: 28962572
[TBL] [Abstract][Full Text] [Related]
13. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
14. New viral vaccines for dermatologic disease.
Urman CO; Gottlieb AB
J Am Acad Dermatol; 2008 Mar; 58(3):361-70. PubMed ID: 18280332
[TBL] [Abstract][Full Text] [Related]
15. The development of cervical cancer and its precursors: what is the role of human papillomavirus infection?
Cox JT
Curr Opin Obstet Gynecol; 2006 Feb; 18 Suppl 1():s5-s13. PubMed ID: 16520683
[TBL] [Abstract][Full Text] [Related]
16. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.
Ginindza TG; Sartorius B; Dlamini X; Östensson E
PLoS One; 2017; 12(5):e0177762. PubMed ID: 28531205
[TBL] [Abstract][Full Text] [Related]
17. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
[TBL] [Abstract][Full Text] [Related]
18. [Expected impact of a quadrivalent HPV vaccine in France].
Riethmuller D; Prétet JL; Denis F; Aubin F; Pradat P; Clavel C; Dachez R; Gondry J; Carcopino X; Mougin C
J Gynecol Obstet Biol Reprod (Paris); 2009 Sep; 38(5):389-95. PubMed ID: 19481365
[TBL] [Abstract][Full Text] [Related]
19. Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model.
Kawai K; de Araujo GT; Fonseca M; Pillsbury M; Singhal PK
BMC Infect Dis; 2012 Oct; 12():250. PubMed ID: 23046886
[TBL] [Abstract][Full Text] [Related]
20. Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection.
Brisson M; Van de Velde N; De Wals P; Boily MC
CMAJ; 2007 Aug; 177(5):464-8. PubMed ID: 17709404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
